ATE259653T1 - Stabile wässrige insulinzubereitungen ohne phenol und kresol - Google Patents
Stabile wässrige insulinzubereitungen ohne phenol und kresolInfo
- Publication number
- ATE259653T1 ATE259653T1 AT99955841T AT99955841T ATE259653T1 AT E259653 T1 ATE259653 T1 AT E259653T1 AT 99955841 T AT99955841 T AT 99955841T AT 99955841 T AT99955841 T AT 99955841T AT E259653 T1 ATE259653 T1 AT E259653T1
- Authority
- AT
- Austria
- Prior art keywords
- cresol
- phenol
- stable aqueous
- insulin preparations
- aqueous insulin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA199801506 | 1998-11-18 | ||
PCT/DK1999/000627 WO2000029013A1 (en) | 1998-11-18 | 1999-11-16 | Stable aqueous insulin preparations without phenol and cresol |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE259653T1 true ATE259653T1 (de) | 2004-03-15 |
Family
ID=8105552
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT99955841T ATE259653T1 (de) | 1998-11-18 | 1999-11-16 | Stabile wässrige insulinzubereitungen ohne phenol und kresol |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1131089B1 (de) |
JP (1) | JP2002529514A (de) |
AT (1) | ATE259653T1 (de) |
AU (1) | AU1263400A (de) |
DE (1) | DE69914934T2 (de) |
WO (1) | WO2000029013A1 (de) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10114178A1 (de) | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität |
CA2460541A1 (en) * | 2001-09-14 | 2003-04-03 | Helle Birk Olsen | Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer |
EP1605967A1 (de) * | 2003-03-13 | 2005-12-21 | Novo Nordisk A/S | Neue nph insulin zubereitungen |
PL1773878T3 (pl) | 2004-07-19 | 2015-07-31 | Biocon Ltd | Koniugaty insulina-oligomer, ich formulacje i zastosowania |
WO2008132229A2 (en) * | 2007-04-30 | 2008-11-06 | Novo Nordisk A/S | Highly concentrated insulin solutions and compositions |
KR101234540B1 (ko) | 2007-10-16 | 2013-02-19 | 바이오콘 리미티드 | 경구 투여가능한 고형 약제학적 조성물 및 그 제조방법 |
US20100069292A1 (en) * | 2008-09-02 | 2010-03-18 | Biodel, Inc. | Insulin with a basal release profile |
RS56632B1 (sr) | 2008-10-17 | 2018-03-30 | Sanofi Aventis Deutschland | Kombinacija insulina i glp-1-agonista |
ES2855146T3 (es) | 2009-11-13 | 2021-09-23 | Sanofi Aventis Deutschland | Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina |
PT3345593T (pt) | 2009-11-13 | 2023-11-27 | Sanofi Aventis Deutschland | Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina |
US8950394B2 (en) | 2010-01-12 | 2015-02-10 | Dance Biopharm Inc. | Preservative-free single dose inhaler systems |
US10842951B2 (en) | 2010-01-12 | 2020-11-24 | Aerami Therapeutics, Inc. | Liquid insulin formulations and methods relating thereto |
US8637458B2 (en) | 2010-05-12 | 2014-01-28 | Biodel Inc. | Insulin with a stable basal release profile |
HUE031181T2 (en) | 2010-08-30 | 2017-06-28 | Sanofi Aventis Deutschland | Use of AVE0010 for the manufacture of a medicament for the treatment of type 2 diabetes |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
CN103917241A (zh) | 2011-08-29 | 2014-07-09 | 赛诺菲-安万特德国有限公司 | 用于2型糖尿病患者中的血糖控制的药物组合 |
AR087744A1 (es) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa |
JP2016505601A (ja) * | 2012-12-26 | 2016-02-25 | ウォックハート リミテッド | 医薬組成物 |
JP6970615B2 (ja) | 2014-12-12 | 2021-11-24 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | インスリングラルギン/リキシセナチド固定比処方 |
WO2016137569A1 (en) * | 2015-02-25 | 2016-09-01 | Dance Biopharm, Inc. | Liquid insulin formulations and methods relating thereto |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4735902A (en) * | 1984-10-23 | 1988-04-05 | Matti Siren | Stabilized composition containing inositoltriphosphate |
US5474978A (en) * | 1994-06-16 | 1995-12-12 | Eli Lilly And Company | Insulin analog formulations |
ATE208208T1 (de) * | 1996-06-20 | 2001-11-15 | Novo Nordisk As | Halogenid-enthaltende insulinzubereitungen |
-
1999
- 1999-11-16 WO PCT/DK1999/000627 patent/WO2000029013A1/en active IP Right Grant
- 1999-11-16 AT AT99955841T patent/ATE259653T1/de not_active IP Right Cessation
- 1999-11-16 DE DE69914934T patent/DE69914934T2/de not_active Expired - Lifetime
- 1999-11-16 AU AU12634/00A patent/AU1263400A/en not_active Abandoned
- 1999-11-16 EP EP99955841A patent/EP1131089B1/de not_active Expired - Lifetime
- 1999-11-16 JP JP2000582059A patent/JP2002529514A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP1131089A1 (de) | 2001-09-12 |
WO2000029013A1 (en) | 2000-05-25 |
DE69914934T2 (de) | 2005-01-05 |
EP1131089B1 (de) | 2004-02-18 |
AU1263400A (en) | 2000-06-05 |
DE69914934D1 (de) | 2004-03-25 |
JP2002529514A (ja) | 2002-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE259653T1 (de) | Stabile wässrige insulinzubereitungen ohne phenol und kresol | |
DE69920767D1 (de) | Stabile konzentrierte Insulin Präparationen zur pulmonaren Verabreichung | |
BR0109272A (pt) | Agentes conjugados terapêuticos de ácido poliglutâmico, métodos para suas preparações e usos | |
AU4916500A (en) | Device for detecting electrical potentials in the forehead-area of a patient | |
ATE442862T2 (de) | Niederviskose konzentrierte proteinformulierungen | |
WO2001026693A3 (en) | Manufacture of polyglutamate-therapeutic agent conjugates | |
DK0948965T3 (da) | Stabile medicinske præparater indeholdende 4,5-epoxymorphinanderivater | |
EE04219B1 (et) | Säilituskindel toimeainekontsentraat formoterooliga | |
EE05000B1 (et) | 2'-asendatud 1,1'-bifenüül-2-karboksamiidid, nende kasutamine ja farmatseutilised preparaadid | |
NO20006138L (no) | Substituerte indolinoner, fremstilling og anvendelse derav som medikamenter | |
WO2000003753A3 (en) | Microdisperse drug delivery systems | |
ATE260650T1 (de) | Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac | |
TR200102385T2 (tr) | Kendiliğinden çözülür N-benzoil staurosporin kompozisyonları. | |
ITTO20010321A0 (it) | Procedimento per la trasmissione di messaggi sms con identita' protetta. | |
ATE454136T1 (de) | Therapeutische zusammensetzungen zur pulmonalen verabreichung | |
ZA200203294B (en) | N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them. | |
DE50114127D1 (de) | Torasemid enthaltende lagerstabile pharmazeutische zubereitungen | |
WO2002024181A3 (en) | The use of melatonin for induction of general anesthesia | |
IT1317841B1 (it) | Derivati del 3,9-diazabiciclo(3.3.1)nonano ad attivita' analgesica. | |
EP1018336A4 (de) | Karzinostatika | |
BR9911960B1 (pt) | composição medicamentosa autoadesiva, e, utilização da mesma. | |
DZ3204A1 (fr) | Dérives de streptogramines, leur préparation et l es compositions qui les contiennent. | |
EE05184B1 (et) | Kaloporosiidi derivaadid, nende valmistamine ja kasutamine ravimina, neid sisaldavad ravimid ning mikroorganismi Gloeoporus dichrous (Fr.:Fr.) tvi ST001714 (DSM 13784) | |
DK1148129T3 (da) | Modifikation af betacellulin | |
HUP0202621A2 (hu) | Javított farmakológiai tulajdonságokkal rendelkező, parenteralis felhasználásra szolgáló ösztramusztin-foszfát készítmények |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |